Clinical Trial Update: A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the TC regimen (docetaxel and carboplatin) with or without nimotuzumab in recurrent metastatic oral squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Xin-Hua Xu | Conditions: Oral Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN